Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Public ClinicalTrials.gov record NCT04924101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
Study identification
- NCT ID
- NCT04924101
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- MK-4830 Biological
- Boserolimab Biological
- Lenvatinib Drug
- Etoposide Drug
- Cisplatin Drug
- Carboplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2021
- Primary completion
- Jun 22, 2025
- Completion
- Jun 22, 2025
- Last update posted
- Jul 22, 2025
2021 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center ( Site 0102) | Gilbert | Arizona | 85234 | — |
| University of Colorado Anschutz Medical Campus ( Site 0104) | Aurora | Colorado | 80045 | — |
| Georgia Cancer Specialists ( Site 0106) | Atlanta | Georgia | 30341 | — |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0130) | Fort Wayne | Indiana | 46845 | — |
| Baptist Health Lexington-Research ( Site 0108) | Lexington | Kentucky | 40503 | — |
| MFSMC-HJWCI-Oncology Research ( Site 0128) | Baltimore | Maryland | 21237 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0122) | Omaha | Nebraska | 68130 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0129) | Omaha | Nebraska | 68130 | — |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0114) | Mineola | New York | 11501 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0115) | New York | New York | 10065 | — |
| Cleveland Clinic-Taussig Cancer Center ( Site 0116) | Cleveland | Ohio | 44195 | — |
| UPMC Hillman Cancer Center ( Site 0127) | Pittsburgh | Pennsylvania | 15232 | — |
| St Francis Cancer Center-Research Office ( Site 0117) | Greenville | South Carolina | 29607 | — |
| Virginia Cancer Institute ( Site 0119) | Richmond | Virginia | 23229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04924101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2025 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04924101 live on ClinicalTrials.gov.